Syneron Medical Ltd. (NASDAQ: ELOS), the leading global aesthetic
device company, today announced fourth quarter 2011 financial
results for the three month period ended December 31, 2011.
Fourth Quarter 2011 Year-Over-Year Financial
Highlights Include:
- Revenue of $61.0 million, up 14.1%
- International revenue of $40.1 million, up 13.8%
- North America revenue of $20.9 million, up 14.5%
- EBU(2) segment revenue of $6.0 million, up 336.3%
- Non-GAAP gross margin of 55.0%, slightly down from 55.6%
- Non-GAAP net income of $1.1 million, compared to $3.6 million
in the prior year
- Net cash and investments portfolio of $171.1 million at
December 31, 2011
Louis P. Scafuri, Chief Executive Officer of Syneron, commented,
"We continued to execute on our growth strategy in the fourth
quarter, as evidenced by the launch of the elos based eLase™ with
Motif™ and eTwo™ facial rejuvenation systems, and the introduction
of our increased utilization accessories that maximize productivity
and profitability for our customers. eLase and eTwo have been very
well received in the market because of their innovative
science-based technology and safe and patient friendly treatment
options, and we expect that they will continue to gain momentum in
the marketplace. In the EBU, growth was driven by the mē home-use
hair removal system, elure skin lightening, and the launch of new
products in the Tända family.
"Turning to 2012, our focus will remain on increasing the top
line, driving mix to higher margin products and consumables,
investing in research and development, and increasing our
profitability. We have several new product launches that we expect
to drive growth, including the launch of our GentleMax Pro, the
most powerful and further enhanced dual wavelength platform in the
market. This industry leading platform will be launched during the
first quarter of 2012. In addition we anticipate the launch of two
exciting new body contouring products in the second half of 2012.
This is complemented by our acquisition of Ultrashape, further
expanding our body sculpting portfolio with an innovative, focused
ultrasound technology for the destruction of fat cells. As part of
our growth strategy we have also decided to expand our focus in the
Chinese market as evidenced by our recent announcement on the
expansion of our product offering in China. Overall, we believe the
Company is well positioned to further expand its market share,
leverage our worldwide channel to market capabilities, and continue
to drive significant growth in the EBU segment."
Non-GAAP Financial Highlights for the Fourth
Quarter Ended December 31, 2011:
Gross Margin: Fourth quarter 2011 non-GAAP
gross margin was 55.0%, compared to 55.6% in fourth quarter 2010
and 53.8% in the third quarter of 2011. The decrease in gross
margin compared to the fourth quarter of 2010 was primarily related
to a higher mix of EBU product sales which currently have lower
gross margins compared to the PAD products. The increase in
non-GAAP gross margin compared to the third quarter of 2011 was
primarily driven by higher production and sales volume and
operational efficiency and costs cutting measures.
Operating Income: Fourth quarter 2011
non-GAAP operating income was $2.2 million, compared to $4.0
million in fourth quarter 2010. Fourth quarter 2011 non-GAAP
operating income represented 3.5% of revenue in the quarter,
compared to 7.5% of revenue in fourth quarter 2010.
The decrease in non-GAAP operating income was primarily related
to an increase in operating expenses associated with the
significant growth in EBU segment revenues. The EBU currently
incurs higher relative operating expenses compared to the PAD
segment due to start-up costs associated with developing and
significant investment in marketing its emerging technologies and
products.
Net Income: Fourth quarter 2011 non-GAAP
net income was $1.1 million, compared to $3.6 million in the fourth
quarter of 2010.
Earnings Per Share: Fourth quarter 2011
non-GAAP earnings per share was $0.03, compared to $0.10 in fourth
quarter 2010.
Non-GAAP net income and earnings per share for fourth quarter
2011 are adjusted to exclude the following one-time items, which
are detailed in the Company's financial tables:
- Amortization of acquired intangible assets of $1.9 million
- Post-acquisition severance accrual of $1.3 million
- Stock-based compensation of $0.9 million
- Other one-time charges and non-recurring costs, net, of $2.9
million
GAAP Financial Highlights for the Fourth
Quarter Ended December 31, 2011:
Gross Margin: Fourth quarter 2011 gross
margin was 53.3%, compared to 53.7% in fourth quarter 2010 and
51.7% in the third quarter of 2011. The decrease in gross margin
compared to the fourth quarter of 2010 was primarily related to a
higher mix of EBU product sales which currently have lower gross
margins compared to the PAD products. The increase in GAAP gross
margin compared to the third quarter of 2011 was primarily driven
by higher production and sales volume and operational efficiency
and costs cutting measures.
Operating Income (Loss): Fourth quarter
2011 operating loss was $5.0 million, compared to operating income
of $8.0 million in fourth quarter 2010.
The decrease in GAAP operating income was primarily a result of
a one-time income of $8.5 million related to the recognition of a
deferred gain related to the Company's merger with Candela
Corporation that was recorded in the fourth quarter of 2010 and an
increase in operating expenses associated with the significant
growth in EBU segment revenues. The EBU currently incurs higher
relative operating expenses compared to the PAD segment due to
start-up costs associated with developing and marketing its
emerging technologies and products.
Net Income (Loss): Fourth quarter 2011 net
loss was $4.8 million, compared to net income of $8.4 million in
fourth quarter of 2010.
Earnings (Loss) Per Share: Fourth quarter
2011 loss per share was $(0.14), compared to earnings per share of
$0.24 in fourth quarter 2010.
Cash Position: As of December 31, 2011,
cash and cash equivalents, including short-term bank deposits and
investments in marketable securities, net were $171.1 million
compared to $177.2 million as of September 30, 2011.
Asaf Alperovitz, Chief Financial Officer of Syneron, commented,
"Non-GAAP operating margin in the Professional Aesthetic Devices,
or PAD, segment was strong at 10.1% despite the increased sales and
marketing efforts to support the launch of our eLase and eTwo
products. Our consolidated results included a higher mix of EBU
revenue, which currently have lower gross margin and higher
relative operating expenses compared to the PAD, impacting our
overall profitability. We continue to balance our efforts to drive
increased profitability in the PAD segment with our investments in
the EBU. We believe there is a great opportunity to increase our
consolidated revenue and margins as we introduce new premium
products in the PAD and EBU segments, benefit from our consumables
revenue model, continue building our brands in the EBU segment and
further leverage our global infrastructure."
Unaudited Non-GAAP segment results for the
three months ended December 31, 2011 and 2010 (in
thousands):
For the three-months ended
---------------------------------------------
December 31, % of December 31, % of % of
2011 Revenues 2010 Revenues Change
------------ -------- ------------ -------- --------
Revenues
PAD $ 55,051 90.2% $ 52,170 97.4% 5.5%
EBU 5,990 9.8% 1,373 2.6% 336.3%
------------ ------------
Total revenues $ 61,041 100.0% $ 53,543 100.0% 14.0%
============ ============
Operating income
(loss)
PAD $ 5,575 10.1% $ 5,948 11.4% (6.3%)
EBU (3,422) (57.1%) (1,926) (140.3%) 77.7%
------------ ------------
Total operating
income $ 2,153 3.5% $ 4,022 7.5% (46.5%)
============ ============
Unaudited Non-GAAP segment results for the
twelve months ended December 31, 2011 and 2010 (in
thousands):
For the twelve-months ended
---------------------------------------------
December 31, % of December 31, % of % of
2011 Revenues 2010 Revenues Change
------------ -------- ------------ -------- --------
Revenues
PAD $ 208,401 91.2% $ 185,951 97.9% 12.1%
EBU 20,041 8.8% 3,927 2.1% 410.3%
------------ ------------
Total revenues $ 228,442 100.0% $ 189,878 100.0% 20.3%
============ ============
Operating income
(loss)
PAD $ 16,835 8.1% $ 302 0.2% 5474.5%
EBU (12,538) (62.6%) (6,117) (155.8%) 105.0%
------------ ------------
Total operating
income (loss) $ 4,297 1.9% $ (5,815) (3.1%) (173.9%)
============ ============
Unaudited GAAP segment results for the three
months ended December 31, 2011 and 2010 (in thousands):
For the three-months ended
---------------------------------------------
December 31, % of December 31, % of % of
2011 Revenues 2010 Revenues Change
------------ -------- ------------ -------- --------
Revenues
PAD $ 55,021 90.2% $ 52,083 97.4% 5.6%
EBU 5,990 9.8% 1,373 2.6% 336.3%
------------ ------------
Total revenues $ 61,011 100.0% $ 53,456 100.0% 14.1%
============ ============
Operating income
(loss)
PAD $ (1,412) (2.6%) $ 9,963 19.1% (114.2%)
EBU (3,539) (59.1%) (1,926) (140.3%) 83.7%
------------ ------------
Total operating
income (loss) $ (4,951) (8.1%) $ 8,037 15.0% (161.6%)
============ ============
Unaudited GAAP segment results for the twelve
months ended December 31, 2011 and 2010 (in thousands):
For the twelve-months ended
---------------------------------------------
December 31, % of December 31, % of % of
2011 Revenues 2010 Revenues Change
------------ -------- ------------ -------- --------
Revenues
PAD $ 208,280 91.2% $ 185,601 97.9% 12.2%
EBU 20,041 8.8% 3,927 2.1% 410.3%
------------ ------------
Total revenues $ 228,321 100.0% $ 189,528 100.0% 20.5%
============ ============
Operating loss
PAD $ (33,001) (15.8%) $ (27,285) (14.7%) 20.9%
EBU (12,655) (63.1%) (6,117) (155.8%) 106.9%
------------ ------------
Total operating loss $ (45,656) (20.0%) $ (33,402) (17.6%) 36.7%
============ ============
Use of Non-GAAP Measures This press
release provides financial measures for gross margin, operating
margin, operating income (loss), net income (loss), earnings (loss)
per share, which exclude one-time expenses relating to the mergers
with Candela Corporation and Primaeva Medical Inc, an expense
charge related to stock-based compensation and amortization,
one-time severance and other one-time charges and non-recurring
costs, and are therefore not calculated in accordance with
generally accepted accounting principles (GAAP). Management
believes that these non-GAAP financial measures provide meaningful
supplemental information regarding our performance because it
reflects our operational results and enhances management's and
investors' ability to evaluate the Company's gross margin,
operating margin, operating income (loss), net income (loss) and
earnings (loss) per share. The presentation of this non-GAAP
financial information is not intended to be considered in isolation
or as a substitute for the financial information prepared and
presented in accordance with GAAP. Management uses both GAAP and
non-GAAP measures when evaluating the business internally and,
therefore, felt it important to make these non-GAAP adjustments
available to investors. A reconciliation of each GAAP to non-GAAP
financial measure discussed in this press release is contained in
the accompanying financial tables.
Conference call Syneron management will
host its fourth quarter 2011 earnings conference call today at 8:30
a.m. ET. Syneron will be broadcasting live via the Investor
Relations section of its website, www.syneron.com. To access the
call, enter the Syneron website, then click on the Investor
Relations - Overview and select "Q4 2011 Results Webcast."
Participants are encouraged to log on at least 15 minutes prior
to the conference call in order to download the applicable audio
software. The call can be heard live or with an on-line replay
which will follow. Those interested in participating in the call
and the question and answer session should dial 877-844-6886 in the
U.S., and 970-315-0315 from overseas. The conference pass code is:
48538831.
About Syneron Medical Ltd. Syneron Medical
Ltd. (NASDAQ: ELOS) is the leading global aesthetic device company
with a comprehensive product portfolio and a global distribution
footprint. The Company's technology enables physicians to provide
advanced solutions for a broad range of medical-aesthetic
applications including body contouring, hair removal, wrinkle
reduction, rejuvenation of the skin's appearance through the
treatment of superficial benign vascular and pigmented lesions, and
the treatment of acne, leg veins and cellulite. The Company sells
its products under two distinct brands, Syneron and Candela.
Founded in 2000, the corporate, R&D, and manufacturing
headquarters for Syneron Medical Ltd. are located in Israel.
Syneron also has R&D and manufacturing operations in the US.
The Company markets and services and supports its products in 90
countries. It has offices in North America, France, Germany, Italy,
Portugal, Spain, UK, Australia, China, Japan, and Hong Kong and
distributors worldwide. Additional information can be found at
www.syneron.com.
SAFE HARBOR FOR FORWARD-LOOKING STATEMENTS
Any statements contained in this document regarding future
expectations, beliefs, goals, plans or prospects constitute
forward-looking statements within the meaning of the Private
Securities Litigation Reform Act of 1995. Further, any statements
that are not statements of historical fact (including statements
containing "believes," "anticipates," "plans," "expects," "may,"
"will," "would," "intends," "estimates" and similar expressions)
should also be considered to be forward-looking statements. There
are a number of important factors that could cause actual results
or events to differ materially from those indicated by such
forward-looking statements, including the risk that the businesses
of Syneron and Candela may not be integrated successfully; the risk
that the merger transaction with Candela may involve unexpected
costs or unexpected liabilities; the risk that synergies from the
merger transaction may not be fully realized or may take longer to
realize than expected; the risk that disruptions from the merger
transaction make it more difficult to maintain relationships with
customers, employees, or suppliers; as well as the risks set forth
in Syneron Medical Ltd.'s most recent Annual Report on Form 20-F,
and the other factors described in the filings that Syneron Medical
Ltd. makes with the SEC from time to time. If one or more of these
factors materialize, or if any underlying assumptions prove
incorrect, Syneron Medical Ltd.'s actual results, performance or
achievements may vary materially from any future results,
performance or achievements expressed or implied by these
forward-looking statements.
In addition, the statements in this document reflect the
expectations and beliefs of Syneron Medical Ltd. as of the date of
this document. Syneron Medical Ltd. anticipates that subsequent
events and developments will cause its expectations and beliefs to
change. However, while Syneron Medical Ltd. may elect to update
these forward-looking statements publicly in the future, it
specifically disclaims any obligation to do so. The forward-looking
statements of Syneron Medical Ltd. do not reflect the potential
impact of any future dispositions or strategic transactions that
may be undertaken. These forward-looking statements should not be
relied upon as representing Syneron Medical Ltd.'s views as of any
date after the date of this document.
Syneron, the Syneron logo, eMatrix and elos are trademarks of
Syneron Medical Ltd. and may be registered in certain
jurisdictions. The elos (Electro-Optical Synergy) technology is a
proprietary technology of Syneron Medical Ltd. All other names are
the property of their respective owners.
(1) PAD: Professional Aesthetic Device segment, which includes
the results of the Syneron and Candela device businesses.
(2) EBU: Emerging Business Units. Products in the EBU include mē
home-use hair removal system, elure Advanced Skin Lightening
products, Tända LED systems, Light Instruments' dental laser
devices along with pipeline products that include Fluorinex teeth
whitening and fluorination.
Syneron Medical Ltd.
Unaudited Condensed Consolidated Statements of Income (Loss)
(in thousands, except per share data)
For the twelve-months
For the three-months ended ended
-------------------------- --------------------------
December 31, December 31, December 31, December 31,
2011 2010 2011 2010
------------ ------------ ------------ ------------
Revenues $ 61,011 $ 53,456 $ 228,321 $ 189,528
Cost of revenues (*) 28,517 24,761 109,203 98,631
------------ ------------ ------------ ------------
Gross profit 32,494 28,695 119,118 90,897
Operating expenses:
Sales and
marketing (*) 19,798 14,944 69,433 65,897
General and
administrative 7,979 6,612 33,730 36,103
Research and
development 6,783 6,414 28,334 26,837
Other expenses
(income), net 2,885 (7,312) 33,277 (4,538)
------------ ------------ ------------ ------------
Total operating
expenses 37,445 20,658 164,774 124,299
------------ ------------ ------------ ------------
Income (Loss) from
operations (4,951) 8,037 (45,656) (33,402)
Other income:
Financial Income,
net 127 419 1,015 717
Other income - 110 35 240
------------ ------------ ------------ ------------
Total other income 127 529 1,050 957
------------ ------------ ------------ ------------
Income (Loss) before
taxes on income
(tax benefit) (4,824) 8,566 (44,606) (32,445)
Taxes on income (tax
benefit) 121 427 3,944 (5,110)
------------ ------------ ------------ ------------
Income (Loss) before
non-controlling
interest (4,945) 8,139 (48,550) (27,335)
Net loss
attributable to
non-controlling
interest 104 244 955 1,799
------------ ------------ ------------ ------------
Net income (loss)
attributable to
Syneron
shareholders $ (4,841) $ 8,383 $ (47,595) $ (25,536)
============ ============ ============ ============
(*) Reclassified
Income (Loss) per
share:
Basic
Income (Loss)
before non-
controlling
interest $ (0.14) $ 0.24 $ (1.38) $ (0.79)
Net loss
attributable to
non-controlling
interest - 0.01 0.03 0.05
------------ ------------ ------------ ------------
Net income (loss)
attributable to
Syneron
shareholders $ (0.14) $ 0.25 $ (1.35) $ (0.74)
------------ ------------ ------------ ------------
Diluted
Income (Loss)
before non-
controlling
interest $ (0.14) $ 0.23 $ (1.38) $ (0.79)
Net loss
attributable to
non-controlling
interest - 0.01 0.03 0.05
------------ ------------ ------------ ------------
Net Income (loss)
attributable to
Syneron
shareholders $ (0.14) $ 0.24 $ (1.35) $ (0.74)
------------ ------------ ------------ ------------
Weighted average
shares outstanding:
Basic 35,307 34,533 35,158 34,369
------------ ------------ ------------ ------------
Diluted 35,307 34,998 35,158 34,369
------------ ------------ ------------ ------------
Syneron Medical Ltd.
Condensed Consolidated Balance Sheets
(in thousands)
December 31, December 31,
2011 2010
------------ ------------
(unaudited) (audited)
Assets
Current assets:
Cash and cash equivalents $ 62,319 $ 63,821
Short-term bank deposits 23,771 1,192
Available-for-sale marketable securities 70,463 114,799
Trade receivable, net 43,300 42,440
Other accounts receivables and prepaid expenses 14,428 13,868
Inventories, net 31,169 22,720
------------ ------------
Total current assets 245,450 258,840
------------ ------------
Long-term assets:
Severance pay fund 295 334
Long-term deposits and others 2,118 2,744
Long-term available-for-sale marketable
securities 15,590 37,721
Investments in affiliated companies 200 7,969
Property and equipment, net 4,155 4,029
Intangible assets, net 31,813 39,639
Goodwill 18,867 18,579
Deferred taxes 4,523 4,930
------------ ------------
Total long-term assets 77,561 115,945
------------ ------------
Total assets $ 323,011 $ 374,785
============ ============
Liabilities and Stockholders' Equity
Current liabilities:
Short term bank credit $ 1,082 $ 2,737
Accounts payable 21,094 16,644
Deferred Revenues 11,550 14,941
Other accounts payable and accrued expenses 38,504 38,191
------------ ------------
Total current liabilities 72,230 72,513
------------ ------------
Long-term liabilities:
Contingent consideration liability 2,535 11,365
Deferred Revenues 4,112 4,528
Warranty Accruals 564 1,074
Accrued severance pay 496 554
Deferred taxes 5,182 6,215
------------ ------------
Total long-term liabilities 12,889 23,736
------------ ------------
Stockholders' equity: 237,892 278,536
------------ ------------
Total liabilities and stockholders' equity $ 323,011 $ 374,785
============ ============
Syneron Medical Ltd.
Unaudited Condensed Consolidated Statements of Cash Flows
(in thousands)
For the twelve months
ended:
--------------------------
December 31, December 31,
2011 2010
------------ ------------
Cash flows from operating activities:
Net loss before non-controlling interest $ (48,550) $ (27,335)
Adjustments to reconcile net loss to net
cash
Share-based compensation 3,400 3,196
Depreciation and amortization 10,348 9,381
Impairments of available-for-sale marketable
securities and other intangible assets 123 1,438
Realized loss, changes in accrued interest
and amortization of premium (discount) on
marketable securities 1,565 716
Impairment of investment in affiliated
company 9,387 850
Bargain purchase price related to
acquisition of a subsidiary - (8,525)
Revaluation of contingent liability (8,830) 1,625
Changes in operating assets and liabilities
Trade receivable, net (2,833) 2,445
Inventories, net (8,581) 13,180
Other accounts receivables (981) 9,667
Deferred taxes (182) (3,339)
Accrued severance pay, net (19) 136
Accounts payable 4,467 4,201
Deferred revenue (3,852) (3,770)
Accrued warranty accruals (299) 199
Other accrued liabilities 140 (6,187)
------------ ------------
Net cash used in operating activities (44,697) (2,122)
------------ ------------
Cash flows from investing activities:
Purchases of property and equipment (2,116) (887)
Investments in long-term deposits and others 326 -
Proceeds from the sale or maturity of
available-for-sale marketable securities 148,612 213,681
Purchase of available-for-sale marketable
securities (83,584) (186,414)
Investments in short-term deposits, net (22,579) (192)
Investments in affiliated and other
companies - (9,169)
Acquisition of shares held by non-
controlling shareholders of a subsidiary (761) -
Net cash received from acquisition of
subsidiary 245 21,427
Other investing activities (55) 367
------------ ------------
Net cash provided by investing activities 40,088 38,813
------------ ------------
Cash flows from financing activities:
Repayment of short term bank credit, net (1,655) -
Proceeds from exercise of stock options 4,054 1,932
------------ ------------
Net cash provided by financing activities 2,399 1,932
------------ ------------
Effect of exchange rates on cash and cash
equivalents 708 826
------------ ------------
Net increase (decrease) in cash and cash
equivalents (1,502) 39,449
Cash and cash equivalents at beginning of period 63,821 24,372
------------ ------------
Cash and cash equivalents at end of period $ 62,319 $ 63,821
============ ============
Syneron Medical Ltd.
Unaudited Non-GAAP Financial Measures and Reconciliation
(in thousands, except per share data)
For the twelve-months
For the three-months ended ended
-------------------------- --------------------------
December 31, December 31, December 31, December 31,
2011 2010 2011 2010
------------ ------------ ------------ ------------
GAAP operating
income (loss) $ (4,951) $ 8,037 $ (45,656) $ (33,402)
Legal settlement
costs - - 33,900 -
Stock-based
compensation 947 692 3,400 3,196
Amortization of
intangible assets 1,920 2,019 7,936 6,668
Merger,
restructuring and
other non-
recurring items,
net 4,237 (6,726) 4,717 17,723
------------ ------------ ------------ ------------
Non-GAAP operating
income (loss) $ 2,153 $ 4,022 $ 4,297 $ (5,815)
============ ============ ============ ============
GAAP net income
(loss) attributable
to Syneron
shareholders $ (4,841) $ 8,383 $ (47,595) $ (25,536)
Legal settlement
costs - - 33,900 -
Stock-based
compensation 947 692 3,400 3,196
Amortization of
intangible assets 1,920 2,019 7,936 6,668
Merger,
restructuring and
other non-
recurring items,
net 4,237 (6,726) 4,717 17,723
Income tax
adjustments (1,195) (760) 117 (8,983)
------------ ------------ ------------ ------------
Non-GAAP net income
(loss) attributable
to Syneron
shareholders $ 1,068 $ 3,608 $ 2,475 $ (6,932)
============ ============ ============ ============
Income (Loss) per
share:
Basic
GAAP net income
(loss) attributable
to Syneron
shareholders $ (0.14) $ 0.24 $ (1.35) $ (0.74)
Legal settlement
costs - - 0.96 -
Stock-based
compensation 0.03 0.02 0.10 0.09
Amortization of
intangible assets 0.05 0.06 0.23 0.19
Merger,
restructuring and
other non-
recurring costs 0.12 (0.20) 0.13 0.52
Income tax
adjustments (0.03) (0.02) 0.00 (0.26)
------------ ------------ ------------ ------------
Non-GAAP net income
(loss) per share
attributable to
Syneron
shareholders $ 0.03 $ 0.10 $ 0.07 $ (0.20)
============ ============ ============ ============
Diluted
GAAP net income
(loss) attributable
to Syneron
shareholders $ (0.14) $ 0.24 $ (1.32) $ (0.74)
Legal settlement
costs - - 0.94 -
Stock-based
compensation 0.03 0.02 0.09 0.09
Amortization of
intangible assets 0.05 0.06 0.22 0.19
Merger,
restructuring and
other non-
recurring costs 0.12 (0.20) 0.13 0.52
Income tax
adjustments (0.03) (0.02) 0.00 (0.26)
------------ ------------ ------------ ------------
Non-GAAP net income
(loss) per share
attributable to
Syneron
shareholders $ 0.03 $ 0.10 $ 0.07 $ (0.20)
============ ============ ============ ============
Weighted average
shares outstanding:
Basic 35,307 34,533 35,158 34,369
------------ ------------ ------------ ------------
Diluted 35,854 35,279 35,946 34,369
------------ ------------ ------------ ------------
Syneron Contacts: Asaf Alperovitz Chief Financial Officer
+ 972 73 244 2283 Email: Email Contact Zack Kubow The Ruth Group
646-536-7020 Email: Email Contact
Syneron Medical Ltd. - Ordinary Shares (NASDAQ:ELOS)
Gráfica de Acción Histórica
De Jun 2024 a Jul 2024
Syneron Medical Ltd. - Ordinary Shares (NASDAQ:ELOS)
Gráfica de Acción Histórica
De Jul 2023 a Jul 2024
